Sean Maduck Sells 75,000 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 75,000 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $65.59, for a total value of $4,919,250.00. Following the transaction, the insider directly owned 8,977 shares of the company’s stock, valued at $588,801.43. The trade was a 89.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Corcept Therapeutics Price Performance

CORT opened at $69.49 on Friday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $91.00. The stock has a market capitalization of $7.46 billion, a price-to-earnings ratio of 198.55 and a beta of 0.36. The business has a fifty day moving average price of $48.02 and a 200 day moving average price of $52.30.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. During the same period in the previous year, the firm earned $0.17 earnings per share. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, research analysts anticipate that Corcept Therapeutics Incorporated will post 0.53 earnings per share for the current year.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CORT shares. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright upped their target price on Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Piper Sandler upped their target price on Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

Institutional Trading of Corcept Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC raised its stake in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares during the last quarter. Hantz Financial Services Inc. raised its stake in Corcept Therapeutics by 598.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 395 shares during the last quarter. Larson Financial Group LLC raised its stake in Corcept Therapeutics by 2,326.3% during the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares during the last quarter. Finally, Gould Capital LLC raised its stake in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.